2025 annual financial data
Recursion Pharmaceuticals 2025 Operating margin
Recursion Pharmaceuticals 2025 operating margin with verified reported values.
Direct answer
Operating margin was -867.87%.
Operating income was -648,132,000 USD and net income was -644,759,000 USD.
Operating cash flow was -371,808,000 USD.
Get free Recursion Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 74,681,000 USD
- Operating income
- -648,132,000 USD
- Net income
- -644,759,000 USD
- Operating cash flow
- -371,808,000 USD